Industries de la santé
05 Mars 2018
When regulatory bodies first approved PCSK9 inhibitors in 2015 for a relatively broad proportion of dyslipidemia patients, payers reacted by placing strict requirements on who is eligible. So far, PCSK9 inhibitors have largely been limited to patients who are unable to lower low-density lipoprotein cholesterol (LDL-C) levels with conventional lipid-lowering therapies. The major barrier to... |Plus d'articles...
- DBV Technologies annonce les résultats de l'étude de Phase II de Viaskin Milk chez les patients allergiques au lait
- Crohn’s disease burden will grow the fastest in France among the 7MM
- Median Technologies annonce ses résultats annuels préliminaires non audités pour l'exercice 2017
- Competition in Chinese medical device market will intensify with ‘Made in China 2025’ plan